• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » HRS13: Arrhythmia Research Technology touts new ECG device

HRS13: Arrhythmia Research Technology touts new ECG device

May 15, 2013 By Ingrid Mezo

HRS13: Arrhythmia Research Technology touts new ECG device

Arrhythmia Research Technology’s (NYSE:HRT) Signal-Averaged Electrocardiography device is 1 of only 2 ECG tests that can predict ventricular arrhythmias in patients with prior heart attacks, data from an NIH-funded multi-center clinical trial proves.

The 22-center trial evaluated 484 patients considered at high risk of ventricular arrhythmias because of low ejection fraction, using more than 10 different ECG-based diagnostic methodologies and algorithms, including 12-lead ECG, 24-hour Holter monitoring, T wave alternans and SAECG-derived parameters, according to a press release from the Fitchburg, Mass.-based company. 

Patients received implantable cardiac defibrillators (ICD) as primary prevention against sudden cardiac death. Data from the trial were released last week at the annual Heart Rhythm Society meeting.

"Our multi-center study rigorously applied a large battery of clinically available ECG test methods," Dr. Wojciech Zareba, Professor of Medicine, Director of the Heart Research Follow Up Program at the University of Rochester and Principal Investigator of this NIH-funded study said in a press statement. "Out of these we found only two ECG-based test results capable of predicting ventricular arrhythmia risk: total root-mean-square voltage of less than 25 microvolts from the SAECG, and greater than 500 ventricular premature beats from 24-hour Holter recordings.

"We are pleased that these results demonstrate an important role of SAECG in the assessment of risk for ventricular tachycardia or fibrillation in post-myocardial infarction patients," Zareba continued.  "These findings may pave the way for more targeted implantation of ICD’s in heart attack patients that are most likely to develop potentially lethal ventricular arrhythmias, and hence benefit from ICD implant."   

Among the major cardiac centers participating in the study were University of Rochester, Duke University, University of Pennsylvania and UMass Memorial Hospital.

Each year approximately 1.5 million Americans suffer a myocardial infarction (MI); these heart attack survivors are susceptible to sudden cardiac death, which claims an estimated 325,000 lives annually, according to Arrhythmia Research Technology.

"We are pleased that our patented SAECG technology made such an important contribution to this study," president and CEO Salvatore Emma Jr. said in a press statement. "The ability for the Company’s PREDICTOR SAECG analysis software to provide better patient selection for ICD implantation is extremely encouraging."

Filed Under: Diagnostics, News Well Tagged With: Arrhythmia Research Technology Inc., Cardiac Rhythm Management, Heart Rhythm Society, HRS 2013

More recent news

  • Medtronic reports first patient treated in study of multi-organ denervation for hypertension
  • Baxter turns to an automation company for its new CEO
  • Pristine Surgical appoints new CFO
  • Boston Scientific wins expanded FDA nod for Farapulse PFA
  • FDA warns on issue with J&J Abiomed pump controllers related to 3 deaths

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy